Printer Friendly

NeoStem signs exclusive license agreement with The Rockefeller University.

M2 PHARMA-September 15, 2014-NeoStem signs exclusive license agreement with The Rockefeller University

(C)2014 M2 COMMUNICATIONS

NeoStem, a company involved in the emerging cellular therapy industry, has signed an exclusive license agreement with The Rockefeller University.

It was reported on Friday that the contract has been signed for patented technologies that further expand the firm's intellectual property portfolio associated with its Targeted Cancer Immunotherapy Programme.

The Rockefeller University patents licensed by NeoStem are entitled 'Methods for use of Apoptotic Cells to Deliver Antigen to Dendritic Cells for Induction or Tolerization of T Cells'. Studies indicated that dendritic cells can be removed from the body in their inactive form, loaded with antigens and then re-infused and activated, leading to an antigen specific immune response, including immune responses directed against cancer antigens.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 15, 2014
Words:141
Previous Article:Array BioPharma hires Dr Victor Sandor as CMO for late-stage clinical programmes.
Next Article:Marina Biotech receives patent protection for comprehensive and diverse nucleic acid delivery platform.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters